Buccal and sublingual vaccine delivery

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 580-592

  Kraan, Heleen ^a   Vrieling, Hilde ^b   Czerkinsky, Cecil ^c   Jiskoot, Wim ^b   Kersten, Gideon ^a,b   Amorij, Jean Pierre ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c INSERM   (France)

Author keywords

Adjuvant; Administration route; Buccal; Dosage form; Sublingual; Vaccine delivery

Indexed keywords

ANTIGENS; IMMUNE SYSTEM;

ADJUVANT; BUCCAL; DOSAGE FORMS; SUBLINGUAL; VACCINE DELIVERY;

VACCINES;

BACTERIAL VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; VACCINE; VIRUS VACCINE; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM; BACTERIAL ENTEROTOXIN; BACTERIAL TOXIN; DISINTEGRATING AGENT; ENTEROTOXIN; LIVE ATTENUATED VIRAL VACCINE; LIVE VACCINE; RECOMBINANT BACTERIAL VACCINE; RECOMBINANT VACCINE; RECOMBINANT VIRUS BASED VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; EXTENDED DRUG RELEASE; FILM; GASTROINTESTINAL MUCOSA; GENITAL SYSTEM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; TABLET DISINTEGRATION; TABLET FORMULATION; VIRUS LIKE AGENT; BUCCAL DRUG ADMINISTRATION; DELAYED RELEASE FORMULATION; SUBLINGUAL DRUG ADMINISTRATION; CHEEK MUCOSA; CLINICAL TRIAL (TOPIC); EXTENDED RELEASE FILM; REVIEW; TABLET; VACCINATION;

ADMINISTRATION, BUCCAL; ADMINISTRATION, SUBLINGUAL; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; VACCINES;

EID: 84906783370     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.060     Document Type: Review

References (83)

1. M.L. Stack et al. Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity Health Aff. (Millwood) 30 6 2011 1021 1028
2. P. Brandtzaeg Function of mucosa-associated lymphoid tissue in antibody formation Immunol. Investig. 39 4-5 2010 303 355
3. J.P. Amorij et al. Towards tailored vaccine delivery: needs, challenges and perspectives J. Control. Release 161 2 2012 363 376
4. J.P. Amorij et al. Needle-free influenza vaccination Lancet Infect. Dis. 10 10 2010 699 711
5. J. Holmgren, and A.M. Svennerholm Vaccines against mucosal infections Curr. Opin. Immunol. 24 3 2012 343 353
6. A. Gebril et al. Optimizing efficacy of mucosal vaccines Expert Rev. Vaccines 11 9 2012 1139 1155
7. B. Slutter, N. Hagenaars, and W. Jiskoot Rational design of nasal vaccines J. Drug Target. 16 1 2008 1 17
8. W.F. Tonnis et al. Pulmonary vaccine delivery: a realistic approach? J. Aerosol Med. Pulm. Drug Deliv. 25 5 2012 249 260
9. J.B. Sun, C. Czerkinsky, and J. Holmgren Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells Scand. J. Immunol. 66 2-3 2007 278 286 (Pubitemid 47063201)
10. R. Valenta et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches J. Intern. Med. 272 2 2012 144 157
11. A. Righi et al. Merkel cells in the oral mucosa Int. J. Surg. Pathol. 14 3 2006 206 211 (Pubitemid 44449059)
12. V.F. Patel, F. Liu, and M.B. Brown Advances in oral transmucosal drug delivery J. Control. Release 153 2 2011 106 116
13. S.M. Bal et al. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release 148 3 2010 266 282
14. Y. Nagai et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice Clin. Exp. Allergy 2014
15. J.H. Song et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination J. Immunol. 182 11 2009 6851 6860
16. P.W. Wertz, and C.A. Squier Cellular and molecular basis of barrier function in oral epithelium Crit. Rev. Ther. Drug Carrier Syst. 8 3 1991 237 269
17. D.J. Aframian, T. Davidowitz, and R. Benoliel The distribution of oral mucosal pH values in healthy saliva secretors Oral Dis. 12 4 2006 420 423 (Pubitemid 43926822)
18. L. Mascarell et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4 + T cells J. Allergy Clin. Immunol. 122 3 2008 603-9e5
19. J.P. Allam et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63 6 2008 720 727
20. K. Eriksson et al. Antigen presentation in the murine oral epithelium Immunology 88 1 1996 147 152 (Pubitemid 26166388)
21. C. Desvignes et al. The murine buccal mucosa is an inductive site for priming class I-restricted CD8 + effector T cells in vivo Clin. Exp. Immunol. 113 3 1998 386 393 (Pubitemid 28410563)
22. E.J. Kunkel, D.J. Campbell, and E.C. Butcher Chemokines in lymphocyte trafficking and intestinal immunity Microcirculation 10 3-4 2003 313 323 (Pubitemid 39004258)
23. C. Hervouet et al. Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells Mucosal Immunol. 7 2 2014 280 291
24. C.W. Cutler, and R. Jotwani Dendritic cells at the oral mucosal interface J. Dent. Res. 85 8 2006 678 689 (Pubitemid 44297321)
25. A.H. Hovav Dendritic cells of the oral mucosa Mucosal Immunol. 7 1 2014 27 37
26. J.H. Song et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection Proc. Natl. Acad. Sci. U. S. A. 105 5 2008 1644 1649
27. H.J. Park et al. Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice PLoS One 7 6 2012 e39921
28. S.H. Kim et al. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection PLoS One 8 9 2013 e75460
29. J.Y. Kim et al. Mucosal immunization with recombinant adenovirus encoding soluble globular head of hemagglutinin protects mice against lethal influenza virus infection Immune Netw. 13 6 2013 275 282
30. D.M. Appledorn et al. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity Clin. Vaccine Immunol. 18 1 2011 150 160
31. W. Domm et al. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier Vaccine 29 40 2011 7080 7089
32. B.S. Shim et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain Virol. J. 9 2012 215
33. J.H. Choi et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs Mol. Pharm. 9 1 2012 156 167
34. J.M. Huang et al. Mucosal delivery of antigens using adsorption to bacterial spores Vaccine 28 4 2010 1021 1030
35. J.H. Amuguni et al. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice Vaccine 29 29-30 2011 4778 4784
36. H. Amuguni et al. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets Microbes Infect. 14 5 2012 447 456
37. M.T. Batista et al. Gut adhesive Bacillus subtilis spores as a platform for the mucosal delivery of antigens Infect. Immun. 82 4 2014 1414 1423
38. Y.H. Fu et al. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice Antiviral Res. 105 2014 72 79
39. L.J. Patterson et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route Clin. Vaccine Immunol. 19 5 2012 629 637
40. S. Murugappan et al. Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine AAPS J. 16 2 2014 342 349
41. S. Gallorini et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses Vaccine 32 20 2014 2382 2388
42. G.K. Pedersen et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP PLoS One 6 11 2011 e26973
43. B.S. Shim et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza PLoS One 6 11 2011 e27953
44. N. Cuburu et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection J. Immunol. 183 12 2009 7851 7859
45. H.J. Cho et al. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16L1 protein with adjuvants Vaccine 28 14 2010 2598 2606
46. S. Kim et al. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant PLoS One 7 2 2012 e32226
47. N. Etchart et al. Dendritic cells recruitment and in vivo priming of CD8 + CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein J. Immunol. 167 1 2001 384 391 (Pubitemid 32567803)
48. C. Hervouet et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract Vaccine 28 34 2010 5582 5590
49. V. Buffa et al. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice PLoS One 7 12 2012 e50529
50. C.F. Huang et al. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice J. Pediatr. Gastroenterol. Nutr. 46 3 2008 262 271
51. C.F. Huang et al. Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis APMIS 119 7 2011 468 478
52. Y.J. Lu et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine Clin. Vaccine Immunol. 17 6 2010 1005 1012
53. S. Raghavan et al. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach Infect. Immun. 78 10 2010 4251 4260
54. C.F. Flach et al. Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice Vaccine 30 9 2012 1636 1643
55. L. Sjokvist Ottsjo et al. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection Infect. Immun. 81 5 2013 1532 1540
56. C.P. O'Meara et al. Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling Immunol. Cell Biol. 92 3 2014 287 297
57. D.R. Negri et al. Persistence of mucosal and systemic immune responses following sublingual immunization Vaccine 28 25 2010 4175 4180
58. N. Cuburu et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice Vaccine 25 51 2007 8598 8610 (Pubitemid 350192038)
59. S. Jun et al. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication Int. Immunol. 24 2 2012 117 128
60. N. Budimir et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity PLoS One 7 1 2012 e30898
61. M. Mutsch et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland N. Engl. J. Med. 350 9 2004 896 903 (Pubitemid 38252537)
62. F.W. van Ginkel et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract Infect. Immun. 73 10 2005 6892 6902 (Pubitemid 41368858)
63. D.J. Lewis et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin PLoS One 4 9 2009 e6999
64. S. Gerber et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA J. Virol. 75 10 2001 4752 4760 (Pubitemid 32381518)
65. X. Lu, J.D. Clements, and J.M. Katz Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine Vaccine 20 7-8 2002 1019 1029 (Pubitemid 34135936)
66. E.B. Norton et al. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant Clin. Vaccine Immunol. 18 4 2011 546 551
67. C.F. Huang et al. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice Scand. J. Immunol. 68 5 2008 502 510
68. Z. Huo et al. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers PLoS One 7 3 2012 e33736
69. PATH Thermoresponsive gel formulations. Vaccine and Pharmaceutical Formulation and Stabilization Technologies Available from: http://sites.path. org/vpfst/formats-routes/mucosal-immunization/thermo-gel/
70. H. Bakke et al. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity Scand. J. Immunol. 63 3 2006 223 231 (Pubitemid 43356784)
71. D.J. Chen Formulation of HPV Dry Powder Wafers for Sublingual Vaccination 2012 University of Colorado at Boulder, Department of Chemistry and Biochemistry
72. F. Tajarobi et al. The impact of dose and solubility of additives on the release from HPMC matrix tablets - identifying critical conditions Pharm. Res. 26 6 2009 1496 1503
73. A. Borde et al. Effect of protein release rates from tablet formulations on the immune response after sublingual immunization Eur. J. Pharm. Sci. 47 4 2012 695 700
74. J.O. Morales, and J.T. McConville Manufacture and characterization of mucoadhesive buccal films Eur. J. Pharm. Biopharm. 77 2 2011 187 199
75. J.P. Amorij et al. Development of stable influenza vaccine powder formulations: challenges and possibilities Pharm. Res. 25 6 2008 1256 1273
76. Y.C. Kim et al. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles J. Control. Release 172 2 2013 579 588
77. C. Edens et al. Measles vaccination using a microneedle patch Vaccine 31 34 2013 3403 3409
78. D. Harris, and J.R. Robinson Drug delivery via the mucous membranes of the oral cavity J. Pharm. Sci. 81 1 1992 1 10
79. U. Kulkarni et al. Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers J. Pharm. Sci. 98 2 2009 471 483
80. P. Brandtzaeg Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann. N. Y. Acad. Sci. 1098 2007 288 311 (Pubitemid 47092533)
81. M. Villavedra et al. "PERFEXT": a direct method for quantitative assessment of cytokine production in vivo at the local level Res. Immunol. 148 4 1997 257 266 (Pubitemid 27381875)
82. C. Czerkinsky, and J. Holmgren Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues Curr. Top. Microbiol. Immunol. 354 2012 1 18
83. G. Saletti et al. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood Nat. Protoc. 8 6 2013 1073 1087